Enveric Biosciences, Inc.
ENVB
$1.27
$0.010.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -39.08% | 80.67% | |||
| Depreciation & Amortization | -1.82% | -2.71% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.08% | 52.35% | |||
| Operating Income | 31.08% | -52.35% | |||
| Income Before Tax | 30.58% | -51.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.74% | -51.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.74% | -51.37% | |||
| EBIT | 31.08% | -52.35% | |||
| EBITDA | 31.86% | -54.69% | |||
| EPS Basic | 74.67% | -33.60% | |||
| Normalized Basic EPS | 74.62% | -33.30% | |||
| EPS Diluted | 74.67% | -33.60% | |||
| Normalized Diluted EPS | 74.62% | -33.30% | |||
| Average Basic Shares Outstanding | 173.47% | 13.31% | |||
| Average Diluted Shares Outstanding | 173.47% | 13.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||